Sei sulla pagina 1di 20

Literature survey

Journals covered Prous Drug Data reports

Vol 22 2000 to 2004 Vol 26 (3)

Classified as the following


1. Natural products and analogs.
2. Synthetic molecules with target.
3. Synthetic molecules without target.

2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
2005- SRN
Final analysis
MIC Intracellu
Compds Target MICtb Ic50 Efficacy Tox
mycobacteria lar
Natural products
Tuberactomycin analogs No target 0.2-6.25 N N N
Erythromycin analog Ribosome 2-Jan 0.4 -4 N N
Capuramycin analogs MraY 1 0.5-8 100nm N N
Synth. with target
7000 fold vero
pteridine analogs DHFR <0.13 NA 1nM N N
cells
Thiolactomycin analog FabH 17
Fluorenes Inh A 4 160nM
Clofazimine analog MOA known 0.5
Mycobactin analog Fe chelator
Synth. without target
10fold vero
Purines unknown 0.78
cells
equiv to No acute tox
Tetracyclic pyrimidines unknown 0.1
SM 1.5g I.p /po
Ec50
Hydrazones unknown 6.25
=0.65
Janssen quinolines unknown 0.01
serine
threonine
Quinoxalines kinases, 2
TNF, Hiv,
HCV etc

2005- SRN